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The aims of this study were to retrospectively review Japanese consecutive cases of polymyositis (PM), dermatomyositis
(DM), and clinically amyopathic dermatomyositis (CADM), focusing on interstital lung disease (ILD) and malignancy, and
to document any differences in the incidence, clinical features, and impact on prognosis among patients with PM, DM,
and CADM.
We retrospectively reviewed 62 consecutive patients diagnosed with PM, DM, and CADM according to Bohan and
Peter’s criteria (PM/DM) and Sontheimer’s criteria and Gerami’s criteria (CADM), focusing on ILD and malignancy.
ILD occurrence rates were 48 % (11/23) in patients with PM, 46 % (11/24) in DM, and 100 % (15/15) in CADM.
Malignancy occurred during diagnosis or the observation period in 14 patients; 86 % were without ILD, and 64 % were
DM without ILD. Multivariate logistic regression analysis showed that the risk of newly diagnosed malignancy was
significantly lower in patients with ILD [odds ratio, 0.0688; 95 % confidence interval (CI), 0.00127–0.372; p = 0.00190] and
significantly higher in patients with DM (odds ratio, 5.21; 95 % CI, 1.17–23.1; p = 0.0299) than in other patients. Patients
with malignancies had shorter survival than those without malignancies; no clinically meaningful difference in survival
was observed among the different myositis types and for presence of ILD. In CADM-ILD, 80 % fatal cases died from
refractory ILD ≤90 days from the first visit; neither death nor recurrence occurred subsequently.
In conclusion, a positive association between DM and malignancy and a negative association between ILD and
malignancy were noted. In the present study, malignancy was a predictor of poor long-term prognosis, but ILD were
not. ILD associated with CADM contributed greatly to poor short-term prognosis, but neither death nor recurrence
occurred subsequently.
Keywords: Interstitial lung disease; Malignancy; Polymyositis; Dermatomyositis; Clinically amyopathic dermatomyositisIntroduction
Polymyositis (PM) and dermatomyositis (DM) are clas-
sified as idiopathic inflammatory myopathies character-
ized by proximal skeletal muscle weakness and muscle
inflammation. Bohan and Peter’s criteria, which were
published in 1975, are often used for diagnosis (Bohan
and Peter 1975). Unlike PM, DM is associated with a
variety of characteristic rashes, such as the heliotrope* Correspondence: isatoshi0112@gmail.com
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provided the original work is properly creditedrash and Gottron’s papules. Moreover, in 2002, Sonthei-
mer proposed the concept of clinically amyopathic
dermatomyositis (CADM) which has the typical rash of
DM but little or no evidence of myositis (Sontheimer
2002).
Interstitial lung disease (ILD) is an important compli-
cation in patients with PM, DM, and CADM. The occur-
rence of ILD has varied widely from 20 to 80 % among
case series of patients with PM and DM (Marie et al.
2002; Love et al. 1991; Fathi et al. 2008; Connors et al.
2010). The clinicopathological features and prognosis of
ILD vary depending on the type of myositis andle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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associated with CADM is often refractory and rapidly
progressive (Douglas et al. 2001). The ratio of rapidly
progressive ILD to the total population of CADM-ILD
has been reported to be higher in eastern Asia than in
Europe and the US. Although the presence of anti-
aminoacyl tRNA synthetase (anti-ARS) antibodies, such
as anti Jo-1 antibody, is associated with chronic ILD,
anti-MDA5 antibodies are associated with acute/sub-
acute ILD (Sato et al. 2012, 2013).
Moreover, malignancies are also associated with in-
flammatory myopathies. Several population-based cohort
studies have confirmed the increased risk of malignancy
among patients with PM and DM (Sigurgeirsson et al.
1992; Buchbinder et al. 2001; Stockton et al. 2001). The
close relationship between malignancy and inflammatory
myopathy may be because of the paraneoplastic pro-
cesses caused by the expression of common autoantigens
in cancer tissue and muscle tissue in some patients with
PM and DM (Albert and Darnell 2004; Casciola-Rosen
et al. 2005).
Among patients with PM, DM, and CADM, ILD and
malignancies have been considered to be a major cause
of morbidity and mortality. However, there have been
only a few studies on the incidence, clinical characteris-
tics, and clinical course of ILD and malignancy for the
different types of myositis. In addition, the effects of ILD
and malignancy as complications on the outcomes in pa-
tients with PM, DM, and CADM are unclear.
The aims of this study were to retrospectively review
consecutive Japanese cases of PM, DM, and CADM, fo-
cusing on ILD and malignancy, and to document any
differences in the incidence, clinical features, and impact
on prognosis among PM, DM, and CADM.
Patients and methods
Patients and setting
This retrospective study was conducted at Kurashiki
central hospital in Kurashiki City, Okayama, Japan. The
diagnoses of PM and DM were based on Bohan and
Peter’s criteria. The diagnosis of CADM was based on
the criteria of Sontheimer (2002). In addition, patients
who exhibited cutaneous manifestations of DM without
muscle weakness for <6 months and experienced fatal
complications, such as acute or subacute ILD, were also
diagnosed with CADM according to Gerami’s criteria
(Gerami et al. 2006). From January 2005 to December
2012, 62 cases newly diagnosed with PM, DM, and
CADM by two or more physicians (including a rheuma-
tologist) were included in the study. There were no ex-
clusion criteria. The patients were divided into five
groups depending on the type of myositis and presence
of ILD: PM with ILD (PM-ILD; 11 cases), PM without
ILD (PM-no ILD; 12 cases), DM with ILD (DM-ILD; 11cases), DM without ILD (DM-no ILD; 13 cases), and
CADM with ILD (CADM-ILD; 15 cases). No cases of
CADM without ILD were present. The Ethics Commit-
tee of Kurashiki Central Hospital approved this study
protocol.
Clinical and laboratory findings
The clinical and laboratory data used in the study were
based on the patients’ medical records. The factors ex-
amined included gender, age, smoking history, time from
onset to first visit or treatment start, department for the
first visit, symptoms and physical examination, labora-
tory data, and pulmonary function test results.
Radiological findings
All of the patients with ILD underwent high-resolution
computed tomography (HRCT) at the time of diagnosis.
HRCT findings were reviewed and interpreted by two
pulmonologists and one radiologist. Images were
assessed for the predominant lung zone (upper or lower
lobe), predominant distribution (peribronchovascular or
subpleural), presence of consolidation, ground-glass opa-
city, reticular shadow, irregular linear opacity, traction
bronchiectasis, cyst, subpleural curve linear shadow,
thickening of the interlobular septa, emphysema, and
volume loss.
Statistical analysis
Categorical data are presented as numbers (percentages).
Continuous data are presented as the median (interquar-
tile range). Fisher’s exact test was used to compare
categorical data. The Mann–Whitney U-test was used to
compare continuous data. Univariate and multivariate
logistic regression analysis was performed to verify the
risk of newly diagnosed malignancy. Cumulative survival
probabilities were estimated using the Kaplan–Meier
method. A p value of <0.05 was considered statistically
significant.
Ethics approval
Ethics approval was provided by the Ethics Committee
of Kurashiki Central Hospital.
Results
Characteristics
ILD was found in 37 cases (60 %). The ILD occurrence
rates were 48 % (11/23) in patients with PM, 46 % (11/
24) in patients with DM, and 100 % (15/15) in patients
with CADM. No significant differences were observed in
gender, age, and smoking history among the five groups
(Table 1). The median time from the onset of symptoms
to first visit or therapy initiation tended to be short in
the patients with ILD, especially those in the CADM-
ILD group. The Department of Respiratory Medicine
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of ILD was made in the PM-ILD and CADM-ILD
groups. The Department of Rheumatology was most fre-
quently visited in the DM group regardless of ILD
diagnosis.
Regarding skin manifestations, Gottron’s sign was the
most common in the patients with DM (with or without
ILD) and CADM, and no statistically significant differ-
ences were observed among the three groups regarding
exhibition of the typical rash of DM. Muscle weakness
was not observed in the CADM-ILD group, whereas my-
algia was observed in four of 15 cases (27 %) with
CADM-ILD. Respiratory symptoms (dry cough and dys-
pnea on exertion) and fever were more frequently ob-
served in the CADM-ILD group than in the other two
groups with ILD, but the differences were not statisti-
cally significant.
In the CADM-ILD group, no increase in myogenic en-
zymes, such as CPK and aldolase, was observed relative
to those in the other four groups. No differences were
observed in the C-reactive protein, ILD biomarkers, and
pulmonary function test results among the three groups
with ILD. Although all patients were examined, anti-Jo-1
antibody was detected in only three patients. Anti-
MDA5 antibody was detected in eight of 13 patients ex-
amined in the CADM-ILD group.
HRCT findings of ILD
In patients with ILD in all groups, shadows were pre-
dominantly observed in the lower lobe (Table 2). In the
PM-ILD group, peri-bronchovascular consolidation, sug-
gestive of cellular nonspecific interstitial pneumonia
(NSIP), was most frequently observed. On the other
hand, the imaging findings of the DM-ILD group were
relatively diverse. The NSIP pattern and organizing
pneumonia patterns were most frequently suspected.
In the CADM-ILD group, subpleural consolidation or
irregular linear opacity was typically observed. Al-
though HRCT findings of CADM-ILD were often
seemingly mild, many of them were associated with
significant volume loss in the lower lobes or with trac-
tion bronchiectasis. Subpleural curve linear shadow
suggestive of collagen vascular disease was found in
36 %, 64 %, and 47 % of the patients in the PM-ILD,
DM-ILD, and CADM-ILD groups, respectively.
Malignancy as a complication
Malignancy as a complication was observed in 17
patients (Table 3). Three of these patients had past his-
tories of surgical resection for malignancy, and no recur-
rences were subsequently observed. Fourteen patients
were newly detected during the diagnosis of PM, DM,
and CADM or during the observation period, 86 % of
whom were patients without ILD, and 64 % were in theDM-no ILD group. Among the 14 patients with newly
diagnosed malignancy, nine had metastatic and five had
localized malignancies. The most common site of origin
was gastric cancer (three patients), and the most com-
mon type of cancer was adenocarcinoma (five patients).
Multivariate logistic regression analysis showed that
the risk of newly diagnosed malignancy was significantly
lower in the patients with ILD (odds ratio, 0.0688; 95 %
confidence interval (CI), 0.00127–0.372; p = 0.00190)
and significantly higher in the patients with DM (odds
ratio, 5.21; 95 % CI, 1.17–23.1; p = 0.0299).
Treatment
In the patients with PM (with or without ILD) and DM-
no ILD, monotherapy with corticosteroids was the most
common initial treatment (Table 4), whereas six of the
11 patients (55 %) with DM-ILD received combination
therapy with corticosteroids and some kind of immuno-
suppressant. In the CADM-ILD group, initial treatment
consisted of a three-drug combination therapy with cor-
ticosteroids, cyclosporine and cyclophosphamide in six
patients, and combination therapy with corticosteroids
and cyclosporine in six cases. In addition, the initial
treatment consisted of combination therapy with cor-
ticosteroid and cyclophosphamide, monotherapy with
corticosteroid, and no treatment in one patient each.
Treatment for the 14 patients with newly diagnosed
malignancies consisted of surgical resection in six pa-
tients and chemotherapy in seven. Two of the patients
with ILD had malignancies; one patient with DM-ILD
had metastatic breast cancer, and although she under-
went surgery and received chemotherapy (epirubicin,
cyclophosphamide, and docetaxel as an adjuvant chemo-
therapy; S-1 and letrozole for the recurrent cancer), she
died from progression of breast cancer. Another patient
with CADM-ILD had metastatic ovarian cancer, but she
died from an extradural hematoma caused by head
banging before treatment initiation.
Outcomes
The median follow-up period for all patients was
48.2 months (the cut-off date for data collection was
September 18, 2014). In this study, 18 fatal cases were
observed during the follow-up period (one patient in the
PM-ILD, three patients in the PM-no ILD, four patients
in the DM-no ILD group, five patients in the DM-ILD
group, and five patients in the CADM-ILD group)
(Table 4). For the whole population, the most common
cause of death was ILD (33 %; two patients in the DM-
ILD group and four patients in the CADM-ILD group),
followed by aspiration pneumonia (22 %) and malig-
nancy (17 %). Among the patients with ILD, ILD was the
most common cause of death in the patients with DM
and CADM (50 % and 80 %, respectively), whereas no
Table 1 Summary of the clinical characteristics and laboratory data
PM DM CADM
ILD (N = 11) No ILD (N = 12) ILD (N = 11) No ILD (N = 13) ILD (N = 15)
Sex (male/female) 2/9 5/7 2/9 4/9 5/10
Age (%) 66.0 (58.0–72.5) 68.5 (62.3–71.3) 65.0 (53.5–68.0) 68.0 (51.0–78.0) 63.0 (60.5–69.0)
Smoking history (%) 1 (9 %) 6 (50 %) 3 (27 %) 2 (15 %) 6 (40 %)
Days from onset
To 1st visit 44.0 (14.0–109) 184 (59.0–761) 68.0 (29.5–96.5) 97.0 (63.0–238) 17.0 (9.50–38.5)
To treatment 62.0 (24.0–151) 235 (133–902) 80.0 (50.3–175) 127 (108–282) 31.0 (15.5–100)
Department for the first visit (%)
Respiratory medicine 8 (73 %) 0 4 (36 %) 0 9 (60 %)
Rheumatology 3 (27 %) 4 (33 %) 6 (55 %) 8 (62 %) 4 (27 %)
Neurology 0 8 (67 %) 1 (9 %) 3 (23 %) 0
Dermatology 0 0 0 2 (15 %) 2 (13 %)
Symptom and signs (%)
Skin
Gottron’s sign / papule 0 0 6 (55 %) 10 (77 %) 9 (60 %)
Heliotrope eruption 0 0 3 (27 %) 10 (77 %) 8 (53 %)
V / Shawl neck sign 0 1 (8 %) 4 (36 %) 6 (46 %) 4 (27 %)
Mechanic’s hands 0 0 2 (18 %) 1 (8 %) 2 (13 %)
Muscle
Myalgia 3 (27 %) 5 (42 %) 8 (73 %) 2 (15 %) 4 (27 %)
Muscle weakness 10 (91 %) 12 (100 %) 6 (55 %) 13 (100 %) 0
Lung
Dry cough 5 (45 %) 0 3 (27 %) 0 9 (60 %)
Dyspnea on exertion 2 (18 %) 1 (8 %) 2 (18 %) 0 9 (60 %)
Others
Fever 8 (73 %) 1 (8 %) 7 (64 %) 1 (8 %) 12 (80 %)
Laboratory data
C-reactive protein (mg/dl) 1.06 (0.535–3.28) 0.125 (0.0800–0.320) 0.730 (0.330–1.96) 0.320 (0.110–0.610) 1.27 (0.495–2.92)
Krebs von den Lungen-6 (U/ml) 870 (568–1340) 273 (127–288) 648 (297–1020) 241 (234–289) 905 (596–1197)
Surfactant protein D (ng/dl) 119 (68.8–180) 52.3 (45.2–62.0) 70.1 (45.5–182) 23.1 (17.2–73.3) 64.7 (29.8–117)
Aspartate aminotransferase (IU/l) 85.0 (62.0–150) 51.5 (35.5–100) 66.0 (48.0–157) 68.0 (54.0–158) 40.0 (28.5–56.5)
Alanine aminotransferase (IU/l) 50.0 (31.5–111) 27.0 (16.5–75.0) 50.0 (29.0–79.5) 43.0 (28.0–101) 20.0 (17.0–32.5)
Lactate dehydrogenase (IU/l) 571 (429–772) 317 (263–670) 496 (357–645) 513 (441–759) 342 (283–381
Creatine phosphokinase (IU/l) 1547 (599–2657) 1212 (402–3347) 874 (270–3000) 965 (617–4872) 232 (108–316)
Aldolase (U/l) 28.5 (11.1–45.2) 18.1 (5.15–22.8) 15.5 (7.75–31.9) 11.4 (8.40–30.9) 7.40 (3.45–8.95)
Antinuclear antibody (%) 8 (73 %) 7 (58 %) 7 (64 %) 9 (69 %) 8 (53 %)
Anti-Jo-1 antibody (%) 1 (9 %) 0 1 (9 %) 1 (8 %) 0
Anti-MDA5 antibody NA NA NA NA 8/13
Lung function test
%Forced vital capacity 76.5 (59.8–93.8) NA 76.5 (53.0–81.7) NA 83.1 (70.4–91.3)
%Diffusing capacity for carbon monoxide 65.7 (56.0–73.6) NA 61.3 (47.1–64.0) NA 58.2 (54.6–62.4)
Categorical data are presented as numbers (percentages). Continuous data are presented as the median (interquartile range). Abbreviations: NA, not applicable
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ILD, aspiration pneumonia caused by respiratory muscle
weakness was the most common cause of death. All
three patients who died from malignancy had DM.
In the CADM-ILD group, 80 % (four patients) of the
patients who were fatal cases died from refractory ILD
≤90 days from their first visit and were positive for anti-
MDA5 antibody. In the four patients who died from
ILD, the initial treatments were combination therapy
with three drugs (corticosteroids, cyclosporine, and
cyclophosphamide) for one patient, combination therapy
with corticosteroids and cyclosporine for two patients,
and corticosteroids for one patient.
A comparison of the survival curves is shown in Fig. 1.
The patients with malignancies had a shorter duration
of survival than did those without malignancies. The
median overall survival was 1924 days (95 % CI, 41–not
applicable) in the patients with malignancies, whereas
the median overall survival in the patients without ma-
lignancies was immature at the cut-off date. On the
other hand, no clinically meaningful differences were ob-
served in survival among patients with the different
types of myositis and for presence or absence of ILD. In
a comparison of the five groups, the survival curve
showed an initial rapid drop in the CADM-ILD group.
However, neither death nor recurrence was observed
subsequently in the CADM-ILD group. For the patients
with DM, those with malignancies tended to haveTable 2 Comparison of high-resolution computed tomography find






Upper lobe dominant 0 1 (9 %)
Lower lobe dominant 11 (100 %) 11 (100 %)
Peri-bronchovascular 9 (82 %) 5 (45 %)
Subpleural 2 (18 %) 7 (64 %)
Shadow
Consolidatiuon 7 (64 %) 4 (36 %)
Ground glass opacity 1 (9 %) 3 (27 %)
Reticular shadow 3 (27 %) 5 (45 %)
Irregular linear opacity 0 0
Tractionbronchiectasis 9 (82 %) 7 (64 %)
Cyst 0 1 (9 %)
Subpleural curve linear shadow 4 (36 %) 7 (64 %)
Interlobular septa thickening 1 (9 %) 2 (18 %)
Others
Emphysema 2 (18 %) 1 (9 %)
Volume loss 9 (82 %) 6 (55 %)
Categorical data are presented as numbers (percentages) and were analyzed by Fisshorter duration of survival than those without malig-
nancies, but the difference was not statistically signifi-
cant (Fig. 2).
Discussion
In this study, we retrospectively reviewed the medical re-
cords of consecutive patients with PM, DM, and CADM,
focusing on ILD and malignancy, to determine their dif-
ferences in occurrence, clinical features, and impact on
prognosis.
No clinically meaningful difference in overall survival
was observed between presence or absence of ILD in
this study. However, ILD was the most prevalent cause
of death in both the DM-ILD and CADM-ILD groups.
In the DM-ILD group, 50 % of the patients in the fatal
cases died from ILD. One patient received three-drug
combination therapy; however, the patient was refractory
and died 111 days after the first visit. In another patient,
ILD initially improved following combination therapy
with corticosteroids and cyclophosphamide, but relapsed
and rapidly progressed during gradual decrease of corti-
costeroids, which led to death on the 1514th day after
the first visit. In the CADM-ILD group, 80 % of the pa-
tients in the fatal cases died from refractory ILD ≤90 days
from the first visit. On the other hand, in the PM-ILD
group, although 73 % of the patients were treated with
corticosteroid monotherapy as an initial treatment, no
death from ILD occurred. No obvious differences in theings among the patients with polymyositis, dermatomyositis,
CADM-ILD
(N = 15)
p-value (adjusted by Holm method)
PM vs DM PM vs CADM DM vs CADM
0 1.00 1.00 1.00
15 (100 %) - - -
6 (40 %) 0.370 0.150 1.00
11 (73 %) 0.161 0.0460 0.683
7 (47 %) 1.00 1.00 1.00
3 (20 %) 1.00 1.00 1.00
2 (13 %) 1.00 1.00 0.280
4 (27 %) 1.00 0.340 0.340
10 (67 %) 1.00 1.00 1.00
1 (7 %) 1.00 1.00 1.00
7 (47 %) 1.00 1.00 1.00
4 (27 %) 1.00 1.00 1.00
2 (13 %) 1.00 1.00 1.00
13 (87 %) 0.720 1.00 0.280
her’s exact test, adjusted by the Holm method
Table 3 Complication of malignancy
(A) PM DM CADM
ILD (N = 11) No ILD (N = 12) ILD (N = 11) No ILD (N = 13) ILD (N = 15)
Past history
Number of patients 1 1 0 0 1
Primary site gastric (ad) lung (ad) prostate (ad)
Newly diagnosed
Number of patients 0 3 1 9 1
Primary site (histology) CML breast (meta) nasopharyngeal (sq) ovarian (clear)
ML (MALT) lung (sq;1, ad;1)




(B) Odds ratio (95 % CI) P value
Univariate analysis
PM 0.387 (0.0615–1.73) 0.218
DM 5.87 (1.41–30.2) 0.0106
CADM 0.191 (0.00411–1.51) 0.155
ILD 0.0652 (0.00628–0.350) 0.000126
Multivariate analysis
DM 5.21 (1.17–23.1) 0.0299
ILD 0.0688 (0.0127–0.372) 0.00190
Details of complicated malignancies (A); univariate and multivariate logistic regression analysis verified the risk of newly diagnosed malignancy (B)
ad adenocarcinoma, sq squamous cell carcinoma, meta metaplastic carcinoma, clear clear cell, CML chronic myelogenous leukemia, ML malignant lymphoma,
MALT mucosa-associated lymphoid tissue, DLBCL diffuse large B-cell lymphoma
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served among the PM-ILD, DM-ILD, and CADM-ILD
groups at the first visit. However, patients with ILD
complicated with PM, most of which exhibited the
radiological cellular NSIP pattern, may have a favorable
treatment response. According to past studies, PM-ILD
is more responsive to corticosteroid therapy, which re-
sults in a favorable prognosis compared with DM-ILD
and CADM-ILD (Fujisawa et al. 2005, 2014).
With regards to CADM, the poor short-term progno-
sis in the CADM-ILD group observed in this study was
consistent with previous reports (Mukae et al. 2009; Ye
et al. 2007; Schnabel et al. 2003). However, no clinically
meaningful differences in overall survival were observed
among the CADM-ILD group and the other four groups.
One reason may be that neither death nor recurrence
occurred in the patients with CADM-ILD who survived
the acute phase of ILD. To put it another way, the prog-
nosis of CADM-ILD may depend on whether prompt
and intensive treatment can be started. In this study, al-
though 83 % of the CADM-ILD patients treated with
three-drug combination therapy survived, one patient
with corticosteroid monotherapy died from ILD. Inaddition, in the patients initially treated with corticoste-
roids and cyclosporine, 33 % died from ILD and 17 %
needed to add cyclophosphamide later. An effective
treatment regimen has not yet been established for this
condition, but the results of the present study showed
that intense treatment with three-drug combination
therapy in the early phase, a treatment that was consist-
ent with previous recommendations (Nawata et al. 1999;
Yamasaki et al. 2007), may lead to favorable prognosis.
In addition, HRCT findings of CADM were often seem-
ingly mild and hard to detect, so it is important to sus-
pect and detect CADM-ILD in conjunction with the
typical rash, rapidly progressive respiratory symptoms,
and fibrotic findings such as volume loss or traction
bronchiectasis in HRCT.
Malignancy as a complication was observed in 14 cases
(23 %) during the diagnoses of PM, DM, and CADM or
during the observation period in this study. The incidence
of malignancy in inflammatory myopathies has been re-
ported to range from 3 to 40 % (Zampieri et al. 2010;
Buchbinder and Hill 2002), and adenocarcinoma was the
most common histological type of the malignancies asso-
ciated with inflammatory myopathies (Sato et al. 2013;
Table 4 Treatment and outcomes
PM DM CADM
ILD (N = 11) No ILD (N = 12) ILD (N = 11) No ILD (N = 13) ILD (N = 15)
Initial immunosuppressive therapy
Prednisone + Cyclosporine + Cyclophosphamide 1 0 1 0 6
Prednisone + Cyclosporine 1 0 2 0 6
Prednisone + Cyclophosphamide 0 0 1 0 1
Prednisone + Azathioprine 1 3 1 2 0
Prednisone + Tacrolimus 0 0 1 0 0
Prednisone + Methotrexate 0 2 0 1 0
Prednisone 8 5 4 9 1
No therapy 0 2 1 1 1
Treatment for maligancy
Surgical resection 0 1 1 4 0
Chemotherapy 0 2 1 4 0
Outcome
Death (number of patients) 1 3 4 5 5
Days from first visit to death 267 1520 (1179–2125) 376 (232–738) 122 (32–1071) 33 (27–41)
Cause of death Renal failure Aspiration pneumonia ILD (2) Aspiration pneumonia (3) ILD (4)
Hypoglycemia Breast cancer Malignant lymphoma Extradural
hematoma
Sepsis Brainstem infarction lung cancer
Initial immunosuppressive treatment and treatment for malignancies diagnosed simultaneously with the diagnoses of polymyositis, dermatomyositis, and clinically
amyopathic dermatomyositis or during the observation period and outcomes
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2001; Bivalacqua et al. 2007; Whitmore et al. 1994), a find-
ing that is consistent with the results of the present study.
In this study, although only three patients died directly
from malignancy, the patients with malignancies had a
shorter duration of survival than those without malignancy.
Previous studies have also suggested that malignancy was a
predictive factor of PM/DM deterioration (Callen 2000;
Marie et al. 2001). A greater number of deaths caused by
malignancy, even in the present study, would probably be
observed if a longer follow-up period was used. Although
adequate therapy of localized cancer may lead to favorable
outcomes for myopathies, 64 % of the malignancies in this
study were already metastatic at diagnosis. Thus, prompt
investigation and repeated screening for underlying malig-
nancy is very important.
In the present study, multivariate logistic regression
analysis showed that the risk of malignancy was signifi-
cantly higher in the patients with DM than in the other
patients. Some population-based studies have also indi-
cated that the risk of cancer was significantly higher in
patients with DM than in patients with PM (Antiochos
et al. 2009; Airio et al. 1995). Moreover, the risk ofmalignancy was significantly lower in the patients with
ILD. Azuma et al. reported that Japanese patients with
PM/DM/CADM who developed malignancies were less
likely to have the complication of interstitial lung disease
(Azuma et al. 2011). According to a systematic review
and meta-analysis, the risk of malignancy was signifi-
cantly reduced in PM and DM patients who had ILD
(risk ratio 0.41; 95 % CI, 0.19–0.87) (Lu et al. 2014). Fur-
ther studies are needed to elucidate the cause of the
negative association between ILD and malignancy in
patients with PM/DM, but investigation of specific
autoantibodies may contribute to elucidating this
mechanism. Although anti-MDA5 antibodies have been
strongly associated with rapidly progressive ILD, anti-
p155/140 antibodies have been strongly associated with
cancer-associated (juvenile) DM (Kaji et al. 2007;
Chinoy et al. 2007).
A limitation of the present study was that the number
of patients investigated was small, and the distribution
of patients may have been skewed. The occurrence rates
of ILD in PM (48 %) and DM (46 %) were consistent
with those of previous reports (Marie et al. 2002; Love
et al. 1991; Fathi et al. 2008; Connors et al. 2010). On
Fig. 1 Survival curves for the whole population. Comparison of the survival curves with and without malignancy (a), with and without interstitial lung disease (ILD) (b), by the types of myositis (c),









Fig. 2 Survival curves for the patients with dermatomyositis. Comparative investigation of the survival curves with and without malignancy
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in this study. Most of the CADM patients in this study
visited the Department of Respiratory Medicine because
of rapidly progressive respiratory symptoms as a chief
complaint, whereas many of the patients with only rash
may have had very limited contact with a hospital. Some
patients may not have fulfilled the Sontheimer’s criteria
because of the short duration of the typical rash.
Among the patients with CADM, not only the preva-
lence of ILD but also the ratio of patients with rapidly
progressive ILD to the total population of CADM-ILD
has been reported to be higher in eastern Asia than in
Europe and the US (Kang et al. 2005; Yamanishi et al.
1999; Sun et al. 2013; Morganroth et al. 2010). Thus, the
results of this study apply to CADM patients in eastern
Asia but might not apply to CADM patients in Europe
and the US.
In conclusion, a positive association between DM
and malignancy and a negative association between
ILD and malignancy were noted. In the present study,
malignancy as a complication was a predictor of poor
long-term prognosis, but ILD were not. ILD associ-
ated with CADM contributed greatly to poor short-
term prognosis, but neither death nor recurrence
occurred subsequently.
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